The COVID-19 pandemic and the use of benzodiazepines and benzodiazepine-related drugs in Estonia: an interrupted time-series analysis
Authors:
Open Access
- 6 June 2024
- journal article
- research article
- Published by Springer Nature in Child and Adolescent Psychiatry and Mental Health
- Vol. 18 (1) , 1-10
Abstract
Background: The COVID-19 pandemic has posed challenges that worsened people’s mental health. We explored the impact of the COVID-19 pandemic on the mental well-being of the population, as indicated by the prevalence rates of benzodiazepine and benzodiazepine-related drug (BDZ) use. Methods: This population‐based, time‐series analysis included all prescriptions of BDZs dispensed in Estonia between 2012 and 2021. The monthly prevalence rates of BDZ use were calculated. Autoregressive integrated moving average models with pulse and slope intervention functions tested for temporary and long-term changes in monthly prevalence rates after the onset of the COVID-19 pandemic. Results: Throughout the 10-year study period, a total of 5,528,911 BDZ prescriptions were dispensed to 397,436 individuals. A significant temporary increase in the overall prevalence rate of BDZ use in March 2020 (2.698 users per 1000, 95% CI 1.408–3.988) was observed, but there was no statistically significant long-term change. This temporary increase affected all the examined subgroups, except for new users, individuals aged 15–29 years, and prescribing specialists other than general practitioners and psychiatrists. The long-term increase in BDZ use was confined to females aged 15–29 years (0.056 users per 1000 per month, 95% CI 0.033–0.079), while no significant change was observed among males of the same age (0.009 users per 1000 per month, 95% CI – 0.017 to 0.035). Among females aged 15–29 years, a significant long-term increase in BDZ use was observed for anxiety disorders (0.017 users per 1000 per month, 95% CI 0.010–0.023), depressive disorders (0.021 users per 1000 per month, 95% CI 0.012–0.030), and other mental and behavioral disorders (0.020 users per 1000 per month, 95% CI 0.010–0.030), but not for sleep disorders (– 0.008 users per 1000 per month, 95% CI – 0.018–0.002). Conclusion: The COVID-19 pandemic led to a short-term increase in BDZ use immediately after the pandemic was declared. In the long term, young females experienced a sustained increase in BDZ use. The prolonged effect on girls and young women suggests their greater vulnerability. These results underscore the need to effectively address the long-term effects of the pandemic among youth.Keywords
Funding Information
- Estonian Research Council (PRG2218, PRG2218, PRG2218)
This publication has 30 references indexed in Scilit:
- Mapping chronic disease prevalence based on medication use and socio-demographic variables: an application of LASSO on administrative data sources in healthcare in the NetherlandsBMC Public Health, 2021
- Comparing actual and forecasted numbers of unique patients dispensed select medications for opioid use disorder, opioid overdose reversal, and mental health, during the COVID-19 pandemic, United States, January 2019 to May 2020Drug and Alcohol Dependence, 2021
- Gender-based approach on the social impact and mental health in Spain during COVID-19 lockdown: a cross-sectional studyBMJ Open, 2020
- Mental health before and during the COVID-19 pandemic: a longitudinal probability sample survey of the UK populationThe Lancet Psychiatry, 2020
- Estimating disease prevalence from drug utilization data using the Random Forest algorithmEuropean Journal of Public Health, 2019
- Primary health care in transition: Variations in service profiles of general practitioners in Estonia and in Finland between 1993 and 2012Health Policy, 2018
- Data Resource Profile: The Danish National Prescription RegistryInternational Journal of Epidemiology, 2016
- Interrupted time series regression for the evaluation of public health interventions: a tutorialInternational Journal of Epidemiology, 2016
- Benzodiazepines revisited—will we ever learn?Addiction, 2011
- A Validation Study of Patient Interview Data and Pharmacy Records for Antihypertensive, Statin, and Antidepressant Medication Use among Older WomenAmerican Journal of Epidemiology, 2004